H3 Biomedicine boosts its cancer collab with Foundation Medicine

The expanded pact builds on the original 2015 deal between the pair

Eisai’s spinoff unit H3 Biomedicine has expanded its 2015 deal with Foundation Medicine as the pair look for new cancer drivers.

H3, a part of Eisai’s global oncology business group, will “collaborate to interrogate the FoundationCORE dataset, with the goal of expanding the translation of ongoing H3 programs and identifying new, actionable cancer drivers” with Foundation Medicine.

FoundationCORE is the company’s molecular information knowledge base. In a statement, the two said they would “continue to build upon the progress the two companies have made during the collaboration.”


Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

Markus Warmuth, M.D., president and CEO of H3 Biomedicine, said: “Having access, through Foundation Medicine, to a high quality, large-scale data set for identification of novel driver events and clinical translation helps create a competitive edge for H3 within the current oncology drug development market.

“The collaboration with Foundation Medicine has broadened the scope of our clinical programs and has pointed us in new, unique directions and we look forward to continuing this successful collaboration.”

“The genomics data in FoundationCORE is a better reflection of patients seeking treatment in current clinical practice compared with publicly available data sets, and it will continue to evolve as new therapies are adopted,” added Lihua Yu, VP of data science and IT at H3 Biomedicine.

“Thorough computational analysis beyond variant calls allows us to connect genomic aberrations with disease context which can directly impact the trajectory of our pipeline.”

Suggested Articles

Cornell researchers found that inhibiting a long noncoding RNA called SAF caused HIV-infected cells to self-destruct.

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.